Positive outcome in 75% of ctcl patients treated with hybryte™ for 18 weeks

Interim results from fda-funded study reinforces hybryte's ™ rapid response and strong safety profile princeton, n.j. , april 14, 2025 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today interim results from the ongoing open-label, investigator-initiated study (iis) evaluating extended hybryte™ (synthetic hypericin) treatment for up to 54 weeks in patients with early-stage cutaneous t-cell lymphoma (ctcl).
SNGX Ratings Summary
SNGX Quant Ranking